2
ForaCare Suisse AG forms service-oriented partnership with B. Braun
mehr
Storys zum Thema Medicale
Lights Out for Insomnia: New Kanabo Research Study Offers Encouraging Results
Tel Aviv, Israel (ots/PRNewswire) - Kanabo Research (http://www.kanaboresearch.com) is proud to present the promising results of its pre-clinical trial, which brings the company one step closer to providing a safe remedy for insomnia and other sleep disorders, without the risk of dependency or the possibility of an overdose. (Photo: ...
mehrHovione Issues $50 Million Bond
Lisbon (ots/PRNewswire) - Hovione has issued a bond of $50 million US dollars maturing in 2033. (Logo: https://mma.prnewswire.com/media/813604/Hovione_Logo.jpg ) The bond was arranged and subscribed by Banco BPI, S.A.. According to António Almeida, Hovione's CFO, "we issued this bond to strengthen our balance sheet as we embark in a new phase of significant capital expansion. We issued a USD denominated bond because the majority of our sales is in the USA". The bond is ...
mehrZentiva Strengthens European Generic Footprint With Prague Manufacturing Site Investment
Prague (ots/PRNewswire) - Zentiva is investing EUR 30 million to maximize its manufacturing site capabilities in Prague. The investment further strengthens Zentiva's manufacturing footprint and is part of a broader ambition to become the champion of generics in Europe. (Logo: https://mma.prnewswire.com/media/788903/Zentiva_Logo.jpg ) Thomas Koene, Head of Industrial ...
mehrMerck Grants Exclusive License to Vertex for Two DNA Damage Response Inhibitors
Darmstadt, Germany (ots/PRNewswire) - Not intended for UK- or US-based media - Exclusive license grants Vertex one clinical and one pre-clinical DNA-PK inhibitor for use in gene-editing applications in six specific genetic disease areas - Merck retains the rights to both compounds in all other disease areas, including oncology - Merck retains the rights to utilize and ...
mehrPhilogen Announces Collaboration With Celgene
Siena, Italy (ots/PRNewswire) - Philogen S.p.A. (a privately-owned company) today announced that they have entered into a collaboration and license agreement with Celgene, to discover and develop a new class of immunomodulatory therapeutics. (Logo: https://mma.prnewswire.com/media/811555/Philogen_Logo.jpg ) "We are extremely pleased to establish a new collaboration with Celgene, a leader in the discovery and development ...
mehr
Philogen Announces Collaboration
Siena, Italy (ots/PRNewswire) - Philogen S.p.A. (a privately-owned company) today announced that they have entered into a collaboration and license agreement with Novartis to discover and develop a new class of immunomodulatory therapeutics. (Logo: https://mma.prnewswire.com/media/811555/Philogen_Logo.jpg ) "We are extremely pleased to establish a new collaboration with Novartis, a leader in the discovery and development of therapies for cancer patients," commented Dr. ...
mehrPhilogen Announces Drug Discovery Collaboration With Johnson & Johnson Innovation
Siena, Italy (ots/PRNewswire) - Philogen S.p.A., a privately-owned biotechnology company, today announced through its wholly-owned Swiss subsidiary, Philochem AG, a collaboration agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to discover new small molecule-based therapeutics utilizing Philochem's novel ...
mehrMedasense Announces Compatibility with Philips IntelliVue Patient Monitors
Ramat Gan, Israel (ots/PRNewswire) - Medasense Biometrics Ltd., developer of the physiological pain-response monitoring technology (NOL® -- the Nociception Level Index), now supports Philips IntelliVue Patient Monitors for anesthesia and critical care monitoring. (Photo: https://mma.prnewswire.com/media/805789/Medasense_PMD_200_Monitor.jpg ) Commercially available in ...
mehrDebiopharm Group regains the commercial rights to Trelstar® (Triptorelin pamoate) and looks for new partners in North America
Lausanne, Switzerland (ots) - Debiopharm and Allergan agree to transition the rights to commercialize Trelstar to new licensees. Debiopharm is in advanced discussion with a potential partner in Canada and is engaged in a bidding process for US rights. Debiopharm Group(TM) (Debiopharm - www.debiopharm.com), a ...
mehrDaiichi Sankyo Europe Enters into European Licensing Agreement with Esperion for Bempedoic Acid and the Bempedoic Acid / Ezetimibe Combination Tablet
Munich (ots/PRNewswire) - - Daiichi Sankyo Europe will market oral bempedoic acid and bempedoic acid / ezetimibe combination tablet in the European Economic Area and Switzerland - Bempedoic acid is a first-in-class, oral, once-daily ATP Citrate Lyase (ACL) inhibitor that reduces cholesterol and fatty acid synthesis ...
mehrNEMIS Technologies Ltd. Successfully Closes First Seed Financing Round / Swiss Diagnostic Startup Closes Seed Financing Round of CHF 3 Million Within the First Year
mehr
SOPHiA GENETICS Raises $77 Million to Accelerate the Democratization of Data-Driven Medicine
San Francisco (ots/PRNewswire) - SOPHiA GENETICS, a leading health tech company, announced today the closing of a $77 million investment round to accelerate the democratization of Data-Driven Medicine. The round was led by Generation Investment Management, a pioneer of sustainable investing, with offices in London and San Francisco. Generation were joined by Idinvest ...
mehrProBioGen's GlymaxX® ADCC Enhancement Technology Used by Betta Pharmaceuticals
Berlin (ots/PRNewswire) - Bispecific Antibody for Cancer Treatment Optimized by GlymaxX® Technology ProBioGen AG, a premier service & technology provider for complex therapeutic antibodies and glycoproteins, announced today that the company achieved an undisclosed milestone payment from Merus N.V. (Nasdaq: MRUS) based on Merus' grant of an exclusive license to ...
mehrNORGINE B.V. and KOREA PHARMA CO., LTD.
NORGINE B.V. and KOREA PHARMA CO., LTD. Enter Into Exclusive Licence Agreement for the Commercialisation of PLENVU® in the Republic of Korea
Amsterdam and Seoul, South Korea (ots/PRNewswire) - - Norgine to receive a significant upfront payment and undisclosed sums in sales milestones along with double-digit percentage royalties - Norgine retains full commercial rights to PLENVU® in all unlicensed countries NORGINE B.V. (Norgine), a leading European ...
mehrMerck and Pfizer Provide Update on JAVELIN Ovarian 100 Trial of Avelumab in Previously Untreated Advanced Ovarian Cancer
Darmstadt, Germany and New York (ots/PRNewswire) - Not intended for US, Canada and UK-based media Merck and Pfizer Inc. (NYSE: PFE) today announced that data from a planned interim analysis of the Phase III JAVELIN Ovarian 100 study of avelumab* did not support the study's initial hypothesis, and therefore the ...
mehrPOLYTECH Health & Aesthetics GmbH - Quality Made in Germany Pays Off: CE Approval For Breast Implants From One of the International Leading Companies Currently Confirmed
Dieburg, Germany (ots/PRNewswire) - On December 18, 2018, POLYTECH sold the three millionth implant since its establishment in 1986. The company is the only German manufacturer and present in over 75 countries worldwide. All implants are manufactured in the company's own production facilities in Dieburg near ...
mehrMerck Announces EMA Orphan Drug Designation for Bifunctional Immunotherapy M7824 in Biliary Tract Cancer
Darmstadt, Germany (ots/PRNewswire) - The information contained is not intended for distribution in the USA, Canada or the UK - European Medicine Agency (EMA) grants M7824, an investigational bifunctional immunotherapy, orphan drug designation in biliary tract cancer (BTC) - EMA orphan drug designation for M7824 in ...
mehr
Merck Assigns Chimeric Antigen Receptor T-cell (CAR-T) Rights to Intrexon
Darmstadt, Germany (ots/PRNewswire) - Not intended for distribution in the USA, Canada or UK - Agreement enables Merck to maintain an investment in the rapidly advancing oncology field of CAR-T, while focusing its R&D efforts - Intrexon to issue Merck $150 million of Intrexon stock and a $25 million convertible note; Intrexon to receive a $25 million cash investment ...
mehrMerck Announces FDA Orphan Drug Designation for Bifunctional Immunotherapy M7824 in Biliary Tract Cancer
Darmstadt, Germany (ots/PRNewswire) - The information contained is not intended for distribution in the USA, Canada or the UK - FDA grants M7824, an investigational bifunctional immunotherapy, orphan drug designation in biliary tract cancer - First regulatory designation for M7824 following recent presentation of ...
mehrMerck in Agreement With Cyclica for AI-augmented Screening Platform to Expand Research Capabilities
Darmstadt, Germany (ots/PRNewswire) - Not intended for distribution in the USA, Canada or UK - Agreement to screen discovery and early development compounds using artificial intelligence and computational biophysics - Cloud-based in silico platform that screens small molecules to determine polypharmacological ...
mehrCannabis Compliance Inc. and University of Guelph Join to Offer Cannabis Workshops for Graduates
Toronto (ots/PRNewswire) - Cannabis Compliance Inc., ("CCI") of Toronto, Ontario is pleased to partner with University of Guelph to offer cannabis workshops to industry enthusiasts and professionals starting in March 2019. CCI is one of the first cannabis consulting firms in Canada who offers subject matter expertise on licensing applications in adherence with the ...
mehrWorld Congress of Cardiology & Cardiovascular Health 2018 Opens in Dubai
Dubai, Uae (ots/PRNewswire) - - Professor David Wood, President of the World Heart Federation, welcomes more than 5000 cardiologists, doctors, nurses, and health and policy experts from around the world to Dubai for WCC 2018 at a time when the opportunities for a sustainable impact on cardiovascular health have never been greater - World Heart Federation Inaugural ...
mehrHitachi Medical Systems Europe Holding AG
2Hitachi Medical Systems Europe introduces the third generation of non-invasive intracardiac blood flow visualization technology, at EuroEcho Imaging 2018
mehr
DTRA Commits Additional Funds to MeMed's Innovative Bacterial Versus Viral Test and Point-of-Care Platform
Haifa, Israel (ots/PRNewswire) - MeMed's contract with DTRA is expanded to include key verification milestones MeMed today announced DTRA's expanded commitment to their point-of-care immunoassay platform and ground breaking bacterial versus viral host-response test. (Logo: ...
mehrNew Data Indicate That EyeMax Mono, a Lens Tailored Specifically for Patients With Dry Age-related Macular Degeneration (AMD), Offers Significant Improvement in Visual Function
London (ots/PRNewswire) - EyeMax Mono implantation results in an improved mean visual acuity of 18 ETDRS letters and 57% increase in mean reading speed LEH Pharma Ltd, a leading provider of innovative technologies for macular disorders, today announces new data published in the Journal of Refractive Surgery[1], ...
mehrKyowa Kirin Announces POTELIGEO® Receives Marketing Authorisation in Europe for the Treatment of Mycosis Fungoides and Sézary Syndrome
Tokyo (ots/PRNewswire) - POTELIGEO will be the first biologic agent targeting CCR4 to be available for patients in Europe. Kyowa Hakko Kirin Co., Ltd., (Kyowa Kirin) announces today that it has received a European Commission decision granting a marketing authorisation to POTELIGEO® (Generic name: mogamulizumab), a ...
mehrZentiva and PHOENIX Form Strategic Partnership in Europe
Prague (ots/PRNewswire) - Zentiva and PHOENIX joined forces this week for an inaugural Annual Partnership meeting in Prague to kick off a strategic partnership between the two healthcare companies in Europe. (Logo: https://mma.prnewswire.com/media/788903/Zentiva_Logo.jpg ) "At PHOENIX group we believe that Zentiva is an excellent fit for partnering at European level, thanks to their strong heritage, broad portfolio of ...
mehrEUR 500 M class action lawsuit against NOLOTIL painkiller manufacturer Boehringer and distributers / International press conference, Barcelona, 28th November 2018
Barcelona (ots) - The medication NOLOTIL is one of the most widely distributed painkillers worldwide. However, its use has been prohibited in some countries because of adverse side-effects. To this day, NOLOTIL is still prescribed for acute pain in Spain, despite the potentially severe side-effects. The incidence of ...
mehrSAKK - Swiss Group for Clinical Cancer Research
The GIST Group Switzerland, the support group for patients with gastrointestinal stromal tumor, has awarded its science prize for the ninth time.
mehr
Vorherige19202122232425262728Nächste